Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.67 -0.27 (-0.93%)
Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 27,032,645
Open 29.05
Bid (Size) 28.68 (3)
Ask (Size) 28.70 (2)
Prev. Close 28.94
Today's Range 28.53 - 29.08
52wk Range 25.20 - 34.11
Shares Outstanding 5,606,688,356
Dividend Yield 5.72%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
The Covid Era Tech Promises To Reinvent Cancer Treatment
Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
Via Benzinga
Exposures COVID-19

Performance

YTD
-3.57%
-3.57%
1 Month
+1.31%
+1.31%
3 Month
+1.59%
+1.59%
6 Month
+3.43%
+3.43%
1 Year
-15.53%
-15.53%

More News

Read More
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via FinancialNewsMedia
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Via Benzinga
Top 3 Discounted Value Stocks Worth Buying Now
Via Talk Markets
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Via Benzinga
Exposures Product Safety
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Via Benzinga
Exposures COVID-19
Is Summit Therapeutics Stock a Buy?
Via The Motley Fool
Pfizer Unusual Options Activity
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Via Investor's Business Daily
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Via The Motley Fool
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
Via The Motley Fool
3 Ultra-Cheap Stocks That Could Get a Boost From Fed Rate Cuts
Via The Motley Fool
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for a Decade
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Pfizer Advances On Its Cancer Journey
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.